Norelgestromin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Norelgestromin |
| DrugBank ID | DB06713 |
| Brand Names (EU) | Norelgestromin |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.51% |
Approved Indication (EMA)
Female contraception. Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | amenorrhea (disease) | 99.51% | DL |
| 2 | acne (disease) | 98.49% | DL |
| 3 | breast fibrocystic disease | 97.51% | DL |
| 4 | apocrine adenosis of breast | 96.25% | DL |
| 5 | blunt duct adenosis of breast | 96.25% | DL |
| 6 | benign mammary dysplasia | 95.88% | DL |
| 7 | breast abscess | 95.41% | DL |
| 8 | fat necrosis of breast | 95.41% | DL |
| 9 | lactation disease | 95.21% | DL |
| 10 | primary ovarian failure | 95.12% | DL |
| 11 | breast adenosis | 94.98% | DL |
| 12 | scalp dermatosis | 94.41% | DL |
| 13 | tetragametic chimerism | 93.79% | DL |
| 14 | ovarian remnant syndrome | 93.49% | DL |
| 15 | anovulation | 93.49% | DL |
| 16 | symptomatic form of fragile X syndrome in female carrier | 93.46% | DL |
| 17 | partial trisomy/tetrasomy of the short arm of chromosome 12 | 93.45% | DL |
| 18 | partial trisomy/tetrasomy of the short arm of chromosome 18 | 93.44% | DL |
| 19 | partial trisomy/tetrasomy of the short arm of chromosome 5 | 93.38% | DL |
| 20 | polysomy of X chromosome | 93.25% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.